• Recombinant Human IL-12: Source-Limited Overview

  2026-10-20

  The supplied record identifies an ApexBT product by name and SKU but provides no substantive description or study evidence. Interpretation is therefore limited to product identity and documented evidence boundaries.

• IL-7, Human Recombinant: Source-Limited Overview

  2026-10-19

  ApexBT lists P1024 as human recombinant IL-7, but the supplied product information provides no documented mechanism, activity data, study outcomes, or application-specific evidence.

• JPH2 as a Brake on Cardiomyocyte dsRNA Sensing

  2026-10-19

  A 2024 study identified junctophilin-2 (JPH2), best known as an excitation–contraction coupling protein, as a cardiomyocyte-associated double-stranded RNA-binding factor. Across biochemical, cellular and mouse-heart evidence, the authors reported that JPH2 limited access of dsRNA to MDA5 and restrained downstream MAVS/TBK1 and interferon-beta signaling. The findings support a model in which the endoplasmic/sarcoplasmic-reticulum surface helps buffer self-dsRNA, while also leaving important questions about binding specificity, causal competition, disease relevance and translation to human cardiac biology.

• Ibuprofen: Mechanism and Evidence Boundaries

  2026-10-17

  The APExBIO product description identifies Ibuprofen, or 2-[4-(2-methylpropyl)phenyl]propanoic acid, as a non-steroidal anti-inflammatory drug with reported COX-1 and COX-2 inhibitory activity. It also describes anticancer, lipid-related, and analgesic findings across model systems, but provides no identity-matched paper, effect-size dataset, comparator details, or independent evidence sufficient to establish those claims beyond the product documentation.

• IL-7, Human Recombinant: Evidence Boundaries

  2026-10-16

  The cited APExBIO page identifies a catalog item named IL-7, human recombinant, SKU P1024, but the available product information does not document molecular specifications, mechanism, assay performance, or biological outcomes. Without an identity-matched research paper, the product can be discussed only at the level of catalog identity and evidence limitations.

• Sodium Pyruvate: What the Record Supports

  2026-10-16

  The available documentation establishes a catalog-level product identity for Sodium pyruvate, SKU C6218, listed by APExBIO. It does not provide a mechanism, measurement principle, study model, comparator, outcome, formulation specification, or identity-matched research evidence, so biological and performance claims cannot be inferred.

• Recombinant Human IL-12: Evidence Boundaries

  2026-10-15

  The APExBIO listing identifies Recombinant Human IL-12 as product P1126, but provides no product description, mechanism statement, assay information, or identity-matched research evidence. The available record therefore supports only a limited provenance and scope assessment, not claims about molecular composition, biological activity, performance, or clinical applicability.

• Triptolide and AhR–HSF1 Signaling in Pancreatitis

  2026-10-15

  A 2025 murine and cell-based study linked AhR overexpression with protection from acute-pancreatitis-associated tight-junction injury through an RBX1–HSF1 network, while reporting that triptolide blocked this protective phenotype. The evidence supports pathway involvement but does not establish triptolide as a selective AhR antagonist, identify the commercial source used, or demonstrate clinical relevance.

• TLS, STING and B-Cell Activation in ESCC

  2026-10-14

  A 2025 study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and proposes a CD40–STING–TRAF2–IRF4 signaling relationship in tumor-infiltrating B cells. The findings are mechanistically suggestive but do not establish that STING agonist-1 was used or that pharmacological STING activation improves outcomes.

• YZ462 and MRSA: Promise, Evidence, and Limits

  2026-10-13

  A source-grounded overview of a 2025 study reporting that YZ462 damages MRSA membranes, affects biofilms, and showed activity in animal models, while emphasizing the study’s evidentiary limits and the gap between preclinical findings and clinical relevance.

• YZ462 and the Evidence for Anti-MRSA Activity

  2026-10-13

  Guo et al. report that YZ462, a heteroaromatic-aryl compound, showed activity against methicillin-resistant Staphylococcus aureus in cellular, biofilm and animal-model studies. The authors link its effects to membrane disruption, increased permeability, reactive oxygen species and interaction with cardiolipin. These findings support YZ462 as a preclinical lead, but they do not establish clinical efficacy, human safety or applicability across the diversity of MRSA infections.

• Isoprinosine and the CLCC1 Herpesvirus Finding

  2026-10-12

  A preprint identifies CLCC1 as a host factor associated with herpesvirus nuclear egress, but the finding does not establish that Isoprinosine or inosine pranobex targets CLCC1, alters membrane fusion, or provides clinical benefit against herpesvirus infection.

• SNS-032 and SARS-CoV-2 Host-Factor Evidence

  2026-10-12

  Kerr et al. identified vesicle-mediated transport, including Rab11a-linked cargo delivery, as a SARS-CoV-2 release-associated pathway and reported inhibition with CDKI-73. These findings should not be treated as evidence that SNS-032 was tested or that its cancer-model pharmacology translates into antiviral activity.

• What 5′ UTR Comparisons Really Show

  2026-10-11

  A 2026 comparison reports that bovine β-globin 5′ UTR supported stronger translation of several reporter and antigenic proteins than the other tested UTRs. The finding is relevant to mRNA construct design in a narrow experimental context, but it does not establish that EZ Cap™ Mouse IL-12 mRNA (m1Ψ) has superior expression, cytokine activity, delivery, or therapeutic performance.

• Recombinant Human Oncostatin M in HCC Adaptation

  2026-10-10

  Recombinant Human Oncostatin M offers a defined cytokine input for studying how extracellular signaling may intersect with ALKBH5-driven adaptation in hepatocellular carcinoma. This evidence-focused article separates established product biology from emerging hypotheses based on a 2026 sorafenib-resistance study.

8545 records 1/570 page Next 12345 下5页 Last page